Avoid common mistakes on your manuscript.
Correction to: Investigational New Drugs https://doi.org/10.1007/s10637-021-01191-6
The original version of this article unfortunately contained mistakes which are listed below.
1. Page 3: “The median interval from durvalumab administration until the occurrence or exacerbation of pneumonitis was 39.5 days (range: 14–181 days). The median interval from the completion of CRT to the occurrence or exacerbation of pneumonitis was 64.5 days (range: 19–202 days).” must be deleted.
2. Page 4: Changed to “The pneumonitis developed at a median interval of 2.1 months (range: 0.5–6.0 months) after the completion of radiotherapy and a median of 0.5 months (range: 0.0–2.6 months) after the final dose of durvalumab.”
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Nishimura, A., Ono, A., Wakuda, K. et al. Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer. Invest New Drugs 40, 464 (2022). https://doi.org/10.1007/s10637-021-01198-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-021-01198-z